Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).

David R LynchMelanie P ChinMartin B DelatyckiSub H SubramonyManuela CortiJ Chad HoyleSylvia BoeschWolfgang NachbauerCaterina MariottiKatherine D MathewsPaola GiuntiGeorge WilmotTheresa ZesiewiczSusan PerlmanAngie GoldsberryMegan O'GradyColin J Meyer

Published in: Annals of neurology (2020)

In the MOXIe trial, omaveloxolone significantly improved neurological function compared to placebo and was generally safe and well tolerated. It represents a potential therapeutic agent in FA. ANN NEUROL 2021;89:212-225.

Keyphrases

phase iii
clinical trial
study protocol
early onset
randomized controlled trial
phase ii
double blind
placebo controlled